Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities

Tim Cooksley, Monica Girotra, Pamela Ginex, Ruth Ann Gordon, Ronald Anderson, Ada Blidner, Jennifer Choi, Michael Dougan, Ilya Glezerman, Dipti Gupta, Douglas Johnson, Vickie R. Shannon, Maria Suarez-Almazor, Bernardo L. Rapoport*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Immune checkpoint inhibitors (ICIs) have emerged as the newest pillar of cancer treatment, transforming outcomes in melanoma and showing benefit in a range of malignancies. Immune-mediated toxicities, stemming from increased activity within the T cell lineage, range from asymptomatic or mild complications to those that are fulminant and potentially fatal. Immune-mediated endocrinopathies include hypophysitis, thyroiditis, and insulin-dependent diabetes mellitus. These presentations, which may be vague and non-specific, can be life-threatening if not diagnosed and treated appropriately. This review considers the work-up and management of immune-mediated endocrinopathies and also considers the role of advanced practice practitioners in the management of immune-mediated toxicities. These state-of-the-art MASCC recommendations represent a comprehensive overview of the management and clinical work-up in those in whom the diagnosis should be considered.

Original languageEnglish (US)
Pages (from-to)6175-6181
Number of pages7
JournalSupportive Care in Cancer
Volume28
Issue number12
DOIs
StatePublished - Dec 2020

Keywords

  • APPs (advanced practice providers)
  • Corticosteroids
  • Diabetes
  • Hyperglycemia
  • Hypophysitis
  • Thyroiditis

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities'. Together they form a unique fingerprint.

Cite this